Sanofi-Aventis (France) Licenses Anti-Angiogenesis Technology from Shanghai Institutes for Biological Sciences

Published: Dec 06, 2010

December 6, 2010 -- Sanofi-Aventis has in-licensed a technology patent from Shanghai Institutes for Biological Sciences (SIBS) that may lead to an anti-angiogenesis cancer drug. The patent covers SIBS’s discovery of the importance of the Slit-Robo signaling path for tumor vasculature and tumor growth. Sanofi-Aventis paid $60 million upfront, plus payments for additional milestones and royalties on sales. More details....

Back to news